Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and TKI in Relapsed CML
NCT02730195Phase 2Terminated
- Sponsor
- Emory University
- Start
- May 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone in chronic myeloid leukemia (CML), sponsored by Emory University. Primary endpoints: Incidence of Adverse Events and Proportion of Subjects Who Achieve and Maintain Major Molecular Response (MMR) Following a Second Discontinuation of TKI up to 6 months. Started May 2016; status: terminated.
02
Drugs
pioglitazone
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02730195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730195.